EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FHL2 facilitates LUSC growth and therapy resistance through PI3K/AKT/mTOR activation

Lingxian Zhang, Dingguo Wang, Lei Zeng, Shiwei Chen, Kunchao Li, Tiankai Yuan, Jing Wang, Xiong Ma, Shuqiang Zhu, Yongbing Wu

Journal of Biological Chemistry · 2025

DOI: 10.1016/j.jbc.2025.110332 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Lingxian Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi province, China. Hauptthemen laut MEDLINE: Muscle Proteins, LIM-Homeodomain Proteins, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Jiangxi Provincial Department of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Four and a half LIM domain protein 2 (FHL2) plays a key role in tumorigenesis and progression. This study investigated its involvement in lung squamous cell carcinoma (LUSC). Bioinformatics analysis and immunohistochemistry confirmed that FHL2 is significantly upregulated in LUSC tissues and correlates with poor prognosis. Gain and loss experiments demonstrated that FHL2 promotes LUSC cell proliferation, migration, and invasion in vitro, while xenograft models confirmed its role in tumor growth in vivo. Mechanistically, FHL2 interacts with c-Jun and suppresses its ubiquitination, thereby stabilizing the c-Jun protein, upregulating PDK1 expression, and subsequently activating the PAM signaling pathway. Notably, FHL2 overexpression induced afatinib resistance in LUSC cells, and patients with afatinib resistance exhibited high levels of FHL2 expression. Our results demonstrate that FHL2 promotes LUSC progression and induces afatinib resistance by regulating the PAM signaling pathway. FHL2 may serve as a crucial prognostic marker for the survival outcomes of LUSC patients and a promising therapeutic target for their treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscle ProteinsLIM-Homeodomain ProteinsDrug Resistance, NeoplasmProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesTranscription FactorsPhosphatidylinositol 3-KinasesLung NeoplasmsCarcinoma, Squamous CellHumansAnimalsMiceCell ProliferationSignal TransductionCell Line, TumorFemaleMaleMice, NudeGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

FHL2LUSCPDK1afatinibc-Jun

Substanzen

Muscle ProteinsFHL2 protein, humanLIM-Homeodomain ProteinsProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesTranscription FactorsPhosphatidylinositol 3-KinasesMTOR protein, human

Autor:innen und Institutionen

  • Department of Cardiothoracic Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi province, China.
  • Department of Pathology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi province, China.
  • Department of Cardiothoracic Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi province, China. Electronic address: wuyongbing789@163.com.

Förderung

  • National Natural Science Foundation of China
  • Jiangxi Provincial Department of Science and Technology

Zitieren

APA

Zhang, L., Wang, D., Zeng, L., Chen, S., Li, K., Yuan, T., Wang, J., Ma, X., Zhu, S., & Wu, Y. (2025). FHL2 facilitates LUSC growth and therapy resistance through PI3K/AKT/mTOR activation. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.110332

Vancouver

Zhang L, Wang D, Zeng L, Chen S, Li K, Yuan T, et al. FHL2 facilitates LUSC growth and therapy resistance through PI3K/AKT/mTOR activation. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.110332

BibTeX
@article{Zhang2025,
  author = {Zhang, Lingxian and Wang, Dingguo and Zeng, Lei and Chen, Shiwei and Li, Kunchao and Yuan, Tiankai and Wang, Jing and Ma, Xiong and Zhu, Shuqiang and Wu, Yongbing},
  title = {FHL2 facilitates LUSC growth and therapy resistance through PI3K/AKT/mTOR activation},
  journal = {Journal of Biological Chemistry},
  year = {2025},
  doi = {10.1016/j.jbc.2025.110332}
}
Kostenlos starten →